Author name: itservices

Australia Advantage
Blog

The Australia Advantage

Did you know that you can start Phase I trials in Australia without an IND? That’s just one of several strategic benefits biotechs are leveraging to speed up development timelines and reduce costs – while generating globally accepted data.

In this article, we break it down.

Blog, Case Studies

Identifying Foreign Matter in Products

What would you do if you found a piece of unidentified material in your toothpaste today? Would you use it? Would you throw the whole tube away? Or, would you send a complaint to the company..?
Foreign matter is an issue across all industries – from food to medicines and consumer products

Blog, Videos

Unlocking the Power of Ultrasensitive Bioanalysis

🔬 How do you measure complex modality molecules at the lowest possible concentrations?

For modern therapies like antibody-drug conjugates (ADCs) and inhzlation drugs, precise bioanalysis at picogram levels is essential to ensure both efficacy and safety. At Resolian, we specialize in ultrasensitive assays that push the boundaries of detection.

Resolian UK Lab Tours
Videos

UK Lab Tour

Explore our UK labs in these site tours.
The staff may have changed but the capabilities remain.

Blog

Foreign Particulate Matter Solutions for Vaccine Safety

Foreign particulate matter (FPM) in vaccines poses risks to product safety, patient health, and regulatory compliance. With stringent guidelines from agencies like the FDA and EMA, identifying and controlling contaminants is essential to maintaining trust and ensuring safety.

Videos

Oligonucleotide Therapeutics Podcast

Min Meng, Chief Operations Officer at Resolian. The interview focuses on the bioanalysis of oligonucleotide therapeutics, a rapidly evolving area in drug development. Min Meng, with 20+ years of experience in this field, provides valuable insights into the unique challenges and advantages of these therapies.

Scroll to Top